Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis
Background The introduction of oral disease-modifying therapies (DMTs) for relapsing–remitting multiple sclerosis (RRMS) changed algorithms of RRMS treatment. Objectives To compare the effectiveness of treatment with dimethyl fumarate (DMF) and teriflunomide (TRF) in a large multicentre Italian coho...
Gespeichert in:
| Veröffentlicht in: | Journal of neurology 2020-10, Vol.267 (10), p.3008-3020 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3020 |
|---|---|
| container_issue | 10 |
| container_start_page | 3008 |
| container_title | Journal of neurology |
| container_volume | 267 |
| creator | D’Amico, Emanuele Zanghì, Aurora Sciandra, Mariangela Lanzillo, Roberta Callari, Graziella Cortese, Antonio Lus, Giacomo Lucchini, Matteo Buccafusca, Maria Bonavita, Simona Gallo, Antonio Curti, Erica Gajofatto, Alberto Signoriello, Elisabetta Bisecco, Alvino Gobbin, Francesca Ferrò, Maria Teresa Ferrazzano, Gina Sparaco, Maddalena Valentino, Paola Mirabella, Massimiliano Granella, Franco Bresciamorra, Vincenzo Grimaldi, Luigi Maria Edoardo Patti, Francesco |
| description | Background
The introduction of oral disease-modifying therapies (DMTs) for relapsing–remitting multiple sclerosis (RRMS) changed algorithms of RRMS treatment.
Objectives
To compare the effectiveness of treatment with dimethyl fumarate (DMF) and teriflunomide (TRF) in a large multicentre Italian cohort of RRMS patients.
Materials and Methods
Patients with RRMS who received treatment with DMF and TRF between January 1st, 2012 and December 31st, 2018 from twelve MS centers were identified. The events investigated were “time-to-first-relapse”, “time-to-Magnetic-Resonance-Imaging (MRI)-activity” and “time-to-disability-progression”.
Results
1445 patients were enrolled (1039 on DMF, 406 on TRF) and followed for a median of 34 months. Patients on TRF were older (43.5 ± 8.6 vs 38.8 ± 9.2 years), with a predominance of men and higher level of disability (
p
|
| doi_str_mv | 10.1007/s00415-020-09959-1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2410705401</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2837208989</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-2e9126b81f6b2af62af5f91f827963d8e4b3791808a26b769cd2f3f86c34b7533</originalsourceid><addsrcrecordid>eNp9kLtOwzAUhi0EoqXwAgwoEguL4fiW2Gyo3FWJpcyWk9iQKpcSO5X69ri0gMTAcHSG__N_rA-hUwKXBCC78gCcCAwUMCglFCZ7aEw4o5hwofbRGBgHLJjgI3Tk_QIAZAwO0YhRASlTZIyeb6vGhvd1nbihMb0JNln5ZG77ytVD2zVVaa8T0yZPwdRV3CHiOHTYrmwbktIEE1NTr33lj9GBM7W3J7s9Qa_3d_PpI569PDxNb2a4YJkImFpFaJpL4tKcGpfGEU4RJ2mmUlZKy3OWKSJBmohlqSpK6piTacF4ngnGJuhi27vsu4_B-qCbyhe2rk1ru8FryglkIDiQiJ7_QRfd0Mf_RkqyjIJUUkWKbqmi77zvrdPLvooy1pqA3pjWW9M6mtZfpvWm-mxXPeSNLX-efKuNANsCPkbtm-1_b_9T-wmK4IdX</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2837208989</pqid></control><display><type>article</type><title>Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>D’Amico, Emanuele ; Zanghì, Aurora ; Sciandra, Mariangela ; Lanzillo, Roberta ; Callari, Graziella ; Cortese, Antonio ; Lus, Giacomo ; Lucchini, Matteo ; Buccafusca, Maria ; Bonavita, Simona ; Gallo, Antonio ; Curti, Erica ; Gajofatto, Alberto ; Signoriello, Elisabetta ; Bisecco, Alvino ; Gobbin, Francesca ; Ferrò, Maria Teresa ; Ferrazzano, Gina ; Sparaco, Maddalena ; Valentino, Paola ; Mirabella, Massimiliano ; Granella, Franco ; Bresciamorra, Vincenzo ; Grimaldi, Luigi Maria Edoardo ; Patti, Francesco</creator><creatorcontrib>D’Amico, Emanuele ; Zanghì, Aurora ; Sciandra, Mariangela ; Lanzillo, Roberta ; Callari, Graziella ; Cortese, Antonio ; Lus, Giacomo ; Lucchini, Matteo ; Buccafusca, Maria ; Bonavita, Simona ; Gallo, Antonio ; Curti, Erica ; Gajofatto, Alberto ; Signoriello, Elisabetta ; Bisecco, Alvino ; Gobbin, Francesca ; Ferrò, Maria Teresa ; Ferrazzano, Gina ; Sparaco, Maddalena ; Valentino, Paola ; Mirabella, Massimiliano ; Granella, Franco ; Bresciamorra, Vincenzo ; Grimaldi, Luigi Maria Edoardo ; Patti, Francesco ; ITALIAN-DIME-TERI group</creatorcontrib><description>Background
The introduction of oral disease-modifying therapies (DMTs) for relapsing–remitting multiple sclerosis (RRMS) changed algorithms of RRMS treatment.
Objectives
To compare the effectiveness of treatment with dimethyl fumarate (DMF) and teriflunomide (TRF) in a large multicentre Italian cohort of RRMS patients.
Materials and Methods
Patients with RRMS who received treatment with DMF and TRF between January 1st, 2012 and December 31st, 2018 from twelve MS centers were identified. The events investigated were “time-to-first-relapse”, “time-to-Magnetic-Resonance-Imaging (MRI)-activity” and “time-to-disability-progression”.
Results
1445 patients were enrolled (1039 on DMF, 406 on TRF) and followed for a median of 34 months. Patients on TRF were older (43.5 ± 8.6 vs 38.8 ± 9.2 years), with a predominance of men and higher level of disability (
p
< 0.001 for all). Patients on DMF had a higher number of relapses and radiological activity (
p
< .05) at baseline.
Time-varying Cox-model for the event “time-to-first relapse” revealed that no differences were found between the two groups in the first 38 months of treatment (HR
t < 38DMF
= 0.73, CI = 0.52 to 1.03,
p
= 0.079). When the time-on-therapy exceeds 38 months patients on DMF had an approximately 0.3 times lower relapse hazard risk than those who took TRF (HR
t>38DMF
= 3.83, CI = 1.11 to 13.23,
p
= 0.033). Both DMTs controlled similarly MRI activity and disability progression.
Conclusions
Patients on DMF had higher relapse-free survival time than TRF group after the first 38 months on therapy.</description><identifier>ISSN: 0340-5354</identifier><identifier>EISSN: 1432-1459</identifier><identifier>DOI: 10.1007/s00415-020-09959-1</identifier><identifier>PMID: 32506391</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Adult ; Algorithms ; Crotonates - therapeutic use ; Data Analysis ; Dimethyl Fumarate - therapeutic use ; Female ; Humans ; Immunosuppressive Agents - therapeutic use ; Italy ; Magnetic resonance imaging ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Multiple sclerosis ; Multiple Sclerosis, Relapsing-Remitting - diagnostic imaging ; Multiple Sclerosis, Relapsing-Remitting - drug therapy ; Neurology ; Neuroradiology ; Neurosciences ; Oral diseases ; Original Communication ; Patients ; Performance evaluation ; Software ; Toluidines - therapeutic use</subject><ispartof>Journal of neurology, 2020-10, Vol.267 (10), p.3008-3020</ispartof><rights>Springer-Verlag GmbH Germany, part of Springer Nature 2020</rights><rights>Springer-Verlag GmbH Germany, part of Springer Nature 2020.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-2e9126b81f6b2af62af5f91f827963d8e4b3791808a26b769cd2f3f86c34b7533</citedby><cites>FETCH-LOGICAL-c375t-2e9126b81f6b2af62af5f91f827963d8e4b3791808a26b769cd2f3f86c34b7533</cites><orcidid>0000-0001-7494-9057</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00415-020-09959-1$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00415-020-09959-1$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32506391$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>D’Amico, Emanuele</creatorcontrib><creatorcontrib>Zanghì, Aurora</creatorcontrib><creatorcontrib>Sciandra, Mariangela</creatorcontrib><creatorcontrib>Lanzillo, Roberta</creatorcontrib><creatorcontrib>Callari, Graziella</creatorcontrib><creatorcontrib>Cortese, Antonio</creatorcontrib><creatorcontrib>Lus, Giacomo</creatorcontrib><creatorcontrib>Lucchini, Matteo</creatorcontrib><creatorcontrib>Buccafusca, Maria</creatorcontrib><creatorcontrib>Bonavita, Simona</creatorcontrib><creatorcontrib>Gallo, Antonio</creatorcontrib><creatorcontrib>Curti, Erica</creatorcontrib><creatorcontrib>Gajofatto, Alberto</creatorcontrib><creatorcontrib>Signoriello, Elisabetta</creatorcontrib><creatorcontrib>Bisecco, Alvino</creatorcontrib><creatorcontrib>Gobbin, Francesca</creatorcontrib><creatorcontrib>Ferrò, Maria Teresa</creatorcontrib><creatorcontrib>Ferrazzano, Gina</creatorcontrib><creatorcontrib>Sparaco, Maddalena</creatorcontrib><creatorcontrib>Valentino, Paola</creatorcontrib><creatorcontrib>Mirabella, Massimiliano</creatorcontrib><creatorcontrib>Granella, Franco</creatorcontrib><creatorcontrib>Bresciamorra, Vincenzo</creatorcontrib><creatorcontrib>Grimaldi, Luigi Maria Edoardo</creatorcontrib><creatorcontrib>Patti, Francesco</creatorcontrib><creatorcontrib>ITALIAN-DIME-TERI group</creatorcontrib><title>Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis</title><title>Journal of neurology</title><addtitle>J Neurol</addtitle><addtitle>J Neurol</addtitle><description>Background
The introduction of oral disease-modifying therapies (DMTs) for relapsing–remitting multiple sclerosis (RRMS) changed algorithms of RRMS treatment.
Objectives
To compare the effectiveness of treatment with dimethyl fumarate (DMF) and teriflunomide (TRF) in a large multicentre Italian cohort of RRMS patients.
Materials and Methods
Patients with RRMS who received treatment with DMF and TRF between January 1st, 2012 and December 31st, 2018 from twelve MS centers were identified. The events investigated were “time-to-first-relapse”, “time-to-Magnetic-Resonance-Imaging (MRI)-activity” and “time-to-disability-progression”.
Results
1445 patients were enrolled (1039 on DMF, 406 on TRF) and followed for a median of 34 months. Patients on TRF were older (43.5 ± 8.6 vs 38.8 ± 9.2 years), with a predominance of men and higher level of disability (
p
< 0.001 for all). Patients on DMF had a higher number of relapses and radiological activity (
p
< .05) at baseline.
Time-varying Cox-model for the event “time-to-first relapse” revealed that no differences were found between the two groups in the first 38 months of treatment (HR
t < 38DMF
= 0.73, CI = 0.52 to 1.03,
p
= 0.079). When the time-on-therapy exceeds 38 months patients on DMF had an approximately 0.3 times lower relapse hazard risk than those who took TRF (HR
t>38DMF
= 3.83, CI = 1.11 to 13.23,
p
= 0.033). Both DMTs controlled similarly MRI activity and disability progression.
Conclusions
Patients on DMF had higher relapse-free survival time than TRF group after the first 38 months on therapy.</description><subject>Adult</subject><subject>Algorithms</subject><subject>Crotonates - therapeutic use</subject><subject>Data Analysis</subject><subject>Dimethyl Fumarate - therapeutic use</subject><subject>Female</subject><subject>Humans</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Italy</subject><subject>Magnetic resonance imaging</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Multiple sclerosis</subject><subject>Multiple Sclerosis, Relapsing-Remitting - diagnostic imaging</subject><subject>Multiple Sclerosis, Relapsing-Remitting - drug therapy</subject><subject>Neurology</subject><subject>Neuroradiology</subject><subject>Neurosciences</subject><subject>Oral diseases</subject><subject>Original Communication</subject><subject>Patients</subject><subject>Performance evaluation</subject><subject>Software</subject><subject>Toluidines - therapeutic use</subject><issn>0340-5354</issn><issn>1432-1459</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kLtOwzAUhi0EoqXwAgwoEguL4fiW2Gyo3FWJpcyWk9iQKpcSO5X69ri0gMTAcHSG__N_rA-hUwKXBCC78gCcCAwUMCglFCZ7aEw4o5hwofbRGBgHLJjgI3Tk_QIAZAwO0YhRASlTZIyeb6vGhvd1nbihMb0JNln5ZG77ytVD2zVVaa8T0yZPwdRV3CHiOHTYrmwbktIEE1NTr33lj9GBM7W3J7s9Qa_3d_PpI569PDxNb2a4YJkImFpFaJpL4tKcGpfGEU4RJ2mmUlZKy3OWKSJBmohlqSpK6piTacF4ngnGJuhi27vsu4_B-qCbyhe2rk1ru8FryglkIDiQiJ7_QRfd0Mf_RkqyjIJUUkWKbqmi77zvrdPLvooy1pqA3pjWW9M6mtZfpvWm-mxXPeSNLX-efKuNANsCPkbtm-1_b_9T-wmK4IdX</recordid><startdate>20201001</startdate><enddate>20201001</enddate><creator>D’Amico, Emanuele</creator><creator>Zanghì, Aurora</creator><creator>Sciandra, Mariangela</creator><creator>Lanzillo, Roberta</creator><creator>Callari, Graziella</creator><creator>Cortese, Antonio</creator><creator>Lus, Giacomo</creator><creator>Lucchini, Matteo</creator><creator>Buccafusca, Maria</creator><creator>Bonavita, Simona</creator><creator>Gallo, Antonio</creator><creator>Curti, Erica</creator><creator>Gajofatto, Alberto</creator><creator>Signoriello, Elisabetta</creator><creator>Bisecco, Alvino</creator><creator>Gobbin, Francesca</creator><creator>Ferrò, Maria Teresa</creator><creator>Ferrazzano, Gina</creator><creator>Sparaco, Maddalena</creator><creator>Valentino, Paola</creator><creator>Mirabella, Massimiliano</creator><creator>Granella, Franco</creator><creator>Bresciamorra, Vincenzo</creator><creator>Grimaldi, Luigi Maria Edoardo</creator><creator>Patti, Francesco</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-7494-9057</orcidid></search><sort><creationdate>20201001</creationdate><title>Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis</title><author>D’Amico, Emanuele ; Zanghì, Aurora ; Sciandra, Mariangela ; Lanzillo, Roberta ; Callari, Graziella ; Cortese, Antonio ; Lus, Giacomo ; Lucchini, Matteo ; Buccafusca, Maria ; Bonavita, Simona ; Gallo, Antonio ; Curti, Erica ; Gajofatto, Alberto ; Signoriello, Elisabetta ; Bisecco, Alvino ; Gobbin, Francesca ; Ferrò, Maria Teresa ; Ferrazzano, Gina ; Sparaco, Maddalena ; Valentino, Paola ; Mirabella, Massimiliano ; Granella, Franco ; Bresciamorra, Vincenzo ; Grimaldi, Luigi Maria Edoardo ; Patti, Francesco</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-2e9126b81f6b2af62af5f91f827963d8e4b3791808a26b769cd2f3f86c34b7533</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adult</topic><topic>Algorithms</topic><topic>Crotonates - therapeutic use</topic><topic>Data Analysis</topic><topic>Dimethyl Fumarate - therapeutic use</topic><topic>Female</topic><topic>Humans</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Italy</topic><topic>Magnetic resonance imaging</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Multiple sclerosis</topic><topic>Multiple Sclerosis, Relapsing-Remitting - diagnostic imaging</topic><topic>Multiple Sclerosis, Relapsing-Remitting - drug therapy</topic><topic>Neurology</topic><topic>Neuroradiology</topic><topic>Neurosciences</topic><topic>Oral diseases</topic><topic>Original Communication</topic><topic>Patients</topic><topic>Performance evaluation</topic><topic>Software</topic><topic>Toluidines - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>D’Amico, Emanuele</creatorcontrib><creatorcontrib>Zanghì, Aurora</creatorcontrib><creatorcontrib>Sciandra, Mariangela</creatorcontrib><creatorcontrib>Lanzillo, Roberta</creatorcontrib><creatorcontrib>Callari, Graziella</creatorcontrib><creatorcontrib>Cortese, Antonio</creatorcontrib><creatorcontrib>Lus, Giacomo</creatorcontrib><creatorcontrib>Lucchini, Matteo</creatorcontrib><creatorcontrib>Buccafusca, Maria</creatorcontrib><creatorcontrib>Bonavita, Simona</creatorcontrib><creatorcontrib>Gallo, Antonio</creatorcontrib><creatorcontrib>Curti, Erica</creatorcontrib><creatorcontrib>Gajofatto, Alberto</creatorcontrib><creatorcontrib>Signoriello, Elisabetta</creatorcontrib><creatorcontrib>Bisecco, Alvino</creatorcontrib><creatorcontrib>Gobbin, Francesca</creatorcontrib><creatorcontrib>Ferrò, Maria Teresa</creatorcontrib><creatorcontrib>Ferrazzano, Gina</creatorcontrib><creatorcontrib>Sparaco, Maddalena</creatorcontrib><creatorcontrib>Valentino, Paola</creatorcontrib><creatorcontrib>Mirabella, Massimiliano</creatorcontrib><creatorcontrib>Granella, Franco</creatorcontrib><creatorcontrib>Bresciamorra, Vincenzo</creatorcontrib><creatorcontrib>Grimaldi, Luigi Maria Edoardo</creatorcontrib><creatorcontrib>Patti, Francesco</creatorcontrib><creatorcontrib>ITALIAN-DIME-TERI group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>D’Amico, Emanuele</au><au>Zanghì, Aurora</au><au>Sciandra, Mariangela</au><au>Lanzillo, Roberta</au><au>Callari, Graziella</au><au>Cortese, Antonio</au><au>Lus, Giacomo</au><au>Lucchini, Matteo</au><au>Buccafusca, Maria</au><au>Bonavita, Simona</au><au>Gallo, Antonio</au><au>Curti, Erica</au><au>Gajofatto, Alberto</au><au>Signoriello, Elisabetta</au><au>Bisecco, Alvino</au><au>Gobbin, Francesca</au><au>Ferrò, Maria Teresa</au><au>Ferrazzano, Gina</au><au>Sparaco, Maddalena</au><au>Valentino, Paola</au><au>Mirabella, Massimiliano</au><au>Granella, Franco</au><au>Bresciamorra, Vincenzo</au><au>Grimaldi, Luigi Maria Edoardo</au><au>Patti, Francesco</au><aucorp>ITALIAN-DIME-TERI group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis</atitle><jtitle>Journal of neurology</jtitle><stitle>J Neurol</stitle><addtitle>J Neurol</addtitle><date>2020-10-01</date><risdate>2020</risdate><volume>267</volume><issue>10</issue><spage>3008</spage><epage>3020</epage><pages>3008-3020</pages><issn>0340-5354</issn><eissn>1432-1459</eissn><abstract>Background
The introduction of oral disease-modifying therapies (DMTs) for relapsing–remitting multiple sclerosis (RRMS) changed algorithms of RRMS treatment.
Objectives
To compare the effectiveness of treatment with dimethyl fumarate (DMF) and teriflunomide (TRF) in a large multicentre Italian cohort of RRMS patients.
Materials and Methods
Patients with RRMS who received treatment with DMF and TRF between January 1st, 2012 and December 31st, 2018 from twelve MS centers were identified. The events investigated were “time-to-first-relapse”, “time-to-Magnetic-Resonance-Imaging (MRI)-activity” and “time-to-disability-progression”.
Results
1445 patients were enrolled (1039 on DMF, 406 on TRF) and followed for a median of 34 months. Patients on TRF were older (43.5 ± 8.6 vs 38.8 ± 9.2 years), with a predominance of men and higher level of disability (
p
< 0.001 for all). Patients on DMF had a higher number of relapses and radiological activity (
p
< .05) at baseline.
Time-varying Cox-model for the event “time-to-first relapse” revealed that no differences were found between the two groups in the first 38 months of treatment (HR
t < 38DMF
= 0.73, CI = 0.52 to 1.03,
p
= 0.079). When the time-on-therapy exceeds 38 months patients on DMF had an approximately 0.3 times lower relapse hazard risk than those who took TRF (HR
t>38DMF
= 3.83, CI = 1.11 to 13.23,
p
= 0.033). Both DMTs controlled similarly MRI activity and disability progression.
Conclusions
Patients on DMF had higher relapse-free survival time than TRF group after the first 38 months on therapy.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>32506391</pmid><doi>10.1007/s00415-020-09959-1</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0001-7494-9057</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0340-5354 |
| ispartof | Journal of neurology, 2020-10, Vol.267 (10), p.3008-3020 |
| issn | 0340-5354 1432-1459 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2410705401 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Adult Algorithms Crotonates - therapeutic use Data Analysis Dimethyl Fumarate - therapeutic use Female Humans Immunosuppressive Agents - therapeutic use Italy Magnetic resonance imaging Male Medicine Medicine & Public Health Middle Aged Multiple sclerosis Multiple Sclerosis, Relapsing-Remitting - diagnostic imaging Multiple Sclerosis, Relapsing-Remitting - drug therapy Neurology Neuroradiology Neurosciences Oral diseases Original Communication Patients Performance evaluation Software Toluidines - therapeutic use |
| title | Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T01%3A48%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dimethyl%20fumarate%20vs%20Teriflunomide:%20an%20Italian%20time-to-event%20data%20analysis&rft.jtitle=Journal%20of%20neurology&rft.au=D%E2%80%99Amico,%20Emanuele&rft.aucorp=ITALIAN-DIME-TERI%20group&rft.date=2020-10-01&rft.volume=267&rft.issue=10&rft.spage=3008&rft.epage=3020&rft.pages=3008-3020&rft.issn=0340-5354&rft.eissn=1432-1459&rft_id=info:doi/10.1007/s00415-020-09959-1&rft_dat=%3Cproquest_cross%3E2837208989%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2837208989&rft_id=info:pmid/32506391&rfr_iscdi=true |